Jyong Biotech (MENS) Prepaid Assets (2024 - 2025)

Jyong Biotech's (MENS) quarterly Prepaid Assets came in at $854000.0 in Q4 2025, up 713.33% year-on-year from $105000.0 in Q4 2024, and up 458.17% quarter-over-quarter from $153000.0 in Q2 2025.

Jyong Biotech (MENS) Prepaid Assets (2024 - 2025) Analysis & Trends

Jyong Biotech's Prepaid Assets history runs 2 years deep, the most recent figure standing at $854000.0 for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 713.33% year-over-year to $854000.0 in Q4 2025; TTM through Dec 2025 was $854000.0, a 713.33% increase from a year earlier, with the FY2025 full-year figure at $854000.0, up 713.33% from the prior year.
  • Prepaid Assets climbed to $854000.0 in Q4 2025 per MENS's latest filing, from $153000.0 in the prior quarter.
  • Across five years, Prepaid Assets topped out at $854000.0 in Q4 2025 and bottomed at $105000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Jyong Biotech 197.86 Mn 197.86 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 854,000.00
Jun 30, 2025 153,000.00
Dec 31, 2024 105,000.00